Stephen Smith, MD
Ophthalmology · Fort Myers, FLNPI 1366438855
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 184 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations.
Across 184 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$653
- AbbVie$463
- Alcon$447
- Biotissue Holdings Inc.$396
- Bausch & Lomb Americas Inc.$374
- Glaukos Corporation$371
- plus $1K from 15 others
Across 284 payments — averaging $2237.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$241K
- AbbVie$186K
- Ocular Therapeutix, Inc.$102K
- Novartis$38K
- Bausch Health US, LLC$28K
- Sun Pharmaceutical Industries Inc.$23K
- plus $17K from 1 others
What the payments were for
- Consulting fees$1003%
- Food & beverage$3,82397%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 55 | $653 |
| AbbVie(2 entities) | 24 | $463 |
| Alcon | 14 | $447 |
| Biotissue Holdings Inc. | 2 | $396 |
| Bausch & Lomb Americas Inc. | 22 | $374 |
| Glaukos Corporation | 12 | $371 |
| Ocular Therapeutix, Inc. | 9 | $242 |
| Mallinckrodt Hospital Products Inc. | 9 | $215 |
| Sun Pharmaceutical Industries Inc. | 9 | $175 |
| Novartis | 5 | $131 |
| Dompe US, Inc. | 4 | $108 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $89 |
| Amgen(2 entities) | 4 | $71 |
| Tarsus Pharmaceuticals, Inc. | 2 | $41 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $29 |
| Sight Sciences, Inc. | 2 | $28 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Rxsight Inc | 1 | $21 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $16 |
| Iridex Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,923 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 133 | $151,133 |
| XiidraLifitegrast | 78 | $82,447 |
| Lotemax SmLoteprednol Etabonate | 193 | $53,810 |
| VyzultaLatanoprostene Bunod | 119 | $52,770 |
| LumiganBimatoprost | 102 | $50,427 |
| BesivanceBesifloxacin Hcl | 122 | $31,810 |
| MieboPerfluorohexyloctane/Pf | 28 | $20,623 |
| RhopressaNetarsudil Mesylate | 31 | $15,385 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 38 | $12,079 |
| Restasis MultidoseCyclosporine | 14 | $10,796 |
| Prednisolone Acetate | 260 | $8,123 |
| ProlensaBromfenac Sodium | 20 | $7,432 |
| TobradexTobramycin/Dexamethasone | 23 | $6,100 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $5,741 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $5,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $463 | $218,097267 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $374 | $155,840225 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Besivance, Prolensa | $89 | $93,053335 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $20 | $15,38531 claims |
| AlconSimbrinza | $447 | $12,07938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Fort Myers
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.